Research programme: gene therapies - Genethon/Cartesian Therapeutics
Latest Information Update: 28 Feb 2025
At a glance
- Originator Genethon; Selecta Biosciences
- Developer Cartesian Therapeutics; Genethon
- Class Gene therapies; Hepatoprotectants
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver disorders
- Discontinued Inborn urea cycle disorders; Muscular dystrophies
Most Recent Events
- 28 Feb 2025 No recent reports of development identified for preclinical development in Liver-disorders in USA (Parenteral)
- 23 Aug 2023 Discontinued - Preclinical for Inborn urea cycle disorders in USA (Parenteral)
- 23 Aug 2023 Discontinued for Muscular dystrophies in USA (Parenteral)